Acrivon Therapeutics
ACRV
ACRV
62 hedge funds and large institutions have $140M invested in Acrivon Therapeutics in 2024 Q4 according to their latest regulatory filings, with 13 funds opening new positions, 18 increasing their positions, 15 reducing their positions, and 5 closing their positions.
New
Increased
Maintained
Reduced
Closed
more first-time investments, than exits
New positions opened: | Existing positions closed:
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
more funds holding
Funds holding: →
more ownership
Funds ownership: →
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
13% less capital invested
Capital invested by funds: $161M → $140M (-$20.8M)
Holders
62
Holding in Top 10
1
Calls
–
Puts
–
Top Buyers
| 1 | +$954K | |
| 2 | +$237K | |
| 3 | +$205K | |
| 4 |
UOC
UBS O'Connor
Chicago,
Illinois
|
+$142K |
| 5 |
PFCS
Pale Fire Capital SE
Prague,
Czech Republic
|
+$91.7K |
Top Sellers
| 1 | -$1.28M | |
| 2 | -$817K | |
| 3 | -$278K | |
| 4 |
PCM
Prelude Capital Management
New York
|
-$264K |
| 5 |
Citadel Advisors
Miami,
Florida
|
-$126K |